Latest article
Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Receives Consensus Suggestion of “Purchase” from Analysts
Tandem Diabetes Care, Inc. (NASDAQ: TNDM) has received an average "buy" rating from the thirteen brokers covering the company, MarketBeat Ratings reports. Four...
Anji Pharma Launches Section three Trial for ANJ900 to Deal with Sort 2 Diabetes...
CAMBRIDGE, Messe & SHANGHAI - (BUSINESS WIRE) - Anji Pharma ("Anji") has initiated a pivotal study...
